{"paper_id":"c418b287-fd26-49cb-9cc0-831a33d45b7b","body_text":"Abstract\nEndometriosis is a complex and chronic estrogen-dependent disease, affecting a significant proportion of women of reproductive age. Despite the long interest and extensive research, the pathogenesis of the disease is still debated. Although available non-invasive diagnostic methods have adequate accuracy, an invasive approach by laparoscopy is often necessary to obtain histological confirmation. In this scenario, the search for an accurate, reliable, cost-effective, clinically applicable non-invasive biomarker plays a crucial role in a potentially early diagnosis and, in this way, shape the future management of the disease. Considering these elements, the current review aims to summarize the most significant and novel results about biomarkers for the diagnosis and follow-up of women affected by endometriosis.\nSimilar content being viewed by others\nReferences\nMissmer SA, Cramer DW. The epidemiology of endometriosis. Obstet Gynecol Clin N Am. 2003;30:1–19 vii.\nBaldi A, Campioni M, Signorile PG. Endometriosis: pathogenesis, diagnosis, therapy and association with cancer (review). Oncol Rep. 2008;19:843–6.\nLaganà AS, Garzon S, Götte M, Viganò P, Franchi M, Ghezzi F, et al. The pathogenesis of endometriosis: molecular and cell biology insights. Int J Mol Sci. 2019;20(22):5615.\nSundqvist J, Andersson KL, Scarselli G, Gemzell-Danielsson K, Lalitkumar PG. Expression of adhesion, attachment and invasion markers in eutopic and ectopic endometrium: a link to the aetiology of endometriosis. Hum Reprod. 2012;27(9):2737–46.\nGarzon S, Laganà AS, Barra F, Casarin J, Cromi A, Raffaelli R, et al. Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development. Expert Opin Investig Drugs. 2020;29:1377–88.\nRiemma G, Laganà AS, Schiattarella A, Garzon S, Cobellis L, Autiero R, et al. Ion channels in the pathogenesis of endometriosis: a cutting-edge point of view. Int J Mol Sci. 2020;21(3):1114.\nDella Corte L, Noventa M, Ciebiera M, Magliarditi M, Sleiman Z, Karaman E, et al. Phytotherapy in endometriosis: an up-to-date review. J Complement Integr Med. 2020;17(3):/j/jcim.2020.17.issue-3/jcim-2019-0084/jcim-2019-0084.xml.\nZondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382:1244–56.\nGarzon S, Laganà AS, Barra F, Casarin J, Cromi A, Raffaelli R, et al. Novel drug delivery methods for improving efficacy of endometriosis treatments. Expert Opin Drug Deliv. 2020;27:1–13. https://doi.org/10.1080/17425247.2021.1829589.\nGhai V, Jan H, Shakir F, Haines P, Kent A. Diagnostic delay for superficial and deep endometriosis in the United Kingdom. J Obstet Gynaecol. 2020;40(1):83–9.\nAnastasiu CV, Moga MA, Elena Neculau A, Bălan A, Scârneciu I, Dragomir RM, et al. Biomarkers for the noninvasive diagnosis of endometriosis: state of the art and future perspectives. Int J Mol Sci. 2020;21(5):1750.\nKrálíčková M, Vetvicka V. Endometriosis and ovarian cancer. World J Clin Oncol. 2014;5:800–5.\nHudson QJ, Ashjaei K, Perricos A, Kuessel L, Husslein H, Wenzl R, et al. Endometriosis patients show an increased M2 response in the peritoneal CD14+low/CD68+low macrophage subpopulation coupled with an increase in the T-helper 2 and T-regulatory cells. Reprod Sci. 2020;27:1920–31.\nOttolina J, Bartiromo L, Dolci C, Salmeri N, Schimberni M, Villanacci R, et al. Assessment of coagulation parameters in women affected by endometriosis: validation study and systematic review of the literature. Diagnostics (Basel). 2020;10:567.\nBerbic M, Fraser IS. Regulatory T cells and other leukocytes in the pathogenesis of endometriosis. J Reprod Immunol. 2011;88:149–55.\nOsuga Y, Koga K, Hirota Y, Hirata T, Yoshino O, Taketani Y. Lymphocytes in endometriosis. Am J Reprod Immunol. 2011;65:1–10.\nGueuvoghlanian-Silva BY, Hernandes C, Correia RP, Podgaec S. Deep infiltrating endometriosis and activation and memory surface markers and cytokine expression in isolated Treg cells. Reprod Sci. 2020;27:599–610.\nMeng Q, Sun W, Jiang J, Fletcher NM, Diamond MP, Saed GM. Identification of common mechanisms between endometriosis and ovarian cancer. J Assist Reprod Genet. 2011;28:917–23.\nPonandai-Srinivasan S, Saare M, Boggavarapu NR, Frisendahl C, Ehrström S, Riethmüller C, et al. Syndecan-1 modulates the invasive potential of endometrioma via TGF-β signalling in a subgroup of women with endometriosis. Hum Reprod. 2020;35:2280–93.\nKaramian A, Paktinat S, Esfandyari S, Nazarian H, Ali Ziai S, Zarnani AH, et al. Pyrvinium pamoate induces in-vitro suppression of IL-6 and IL-8 produced by human endometriotic stromal cells. Hum Exp Toxicol. 2021;40:649–60.\nGica N, Panaitescu AM, Iancu G, Botezatu R, Peltecu G, Gica C. The role of biological markers in predicting infertility associated with non-obstructive endometriosis. Ginekol Pol. 2020;91:189–92.\nShimizu K, Kamada Y, Sakamoto A, Matsuda M, Nakatsuka M, Hiramatsu Y. High expression of high-mobility group box 1 in menstrual blood: implications for endometriosis. Reprod Sci. 2017;24:1532–7.\nSantulli P, Borghese B, Chouzenoux S, Vaiman D, Borderie D, Streuli I, et al. Serum and peritoneal interleukin-33 levels are elevated in deeply infiltrating endometriosis. Hum Reprod. 2012;27:2001–9.\nMiller JE, Monsanto SP, Ahn SH, Khalaj K, Fazleabas AT, Young SL, et al. Interleukin-33 modulates inflammation in endometriosis. Sci Rep. 2017;7:17903.\nDorien O, Waelkens E, Vanhie A, Peterse D, Fassbender A, D’Hooghe T. The use of antibody arrays in the discovery of new plasma biomarkers for endometriosis. Reprod Sci. 2020;27:751–62.\nGuo M, Bafligil C, Tapmeier T, Hubbard C, Manek S, Shang C, et al. Mass cytometry analysis reveals a distinct immune environment in peritoneal fluid in endometriosis: a characterisation study. BMC Med. 2020;18:3.\nSuryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2013;19:1213–24.\nSiufi Neto J, Kho RM, Siufi DF, Baracat EC, Anderson KS, Abrão MS. Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. J Minim Invasive Gynecol. 2014;21:55–63.\nPapari E, Noruzinia M, Kashani L, Foster WG. Identification of candidate microRNA markers of endometriosis with the use of next-generation sequencing and quantitative real-time polymerase chain reaction. Fertil Steril. 2020;113:1232–41.\nGao S, Liu S, Gao ZM, Deng P, Wang DB. Reduced microRNA-451 expression in eutopic endometrium contributes to the pathogenesis of endometriosis. World J Clin Cases. 2019;7:2155–64.\nChen S, Luo Y, Cui L, Yang Q. miR-96-5p regulated TGF-β/SMAD signaling pathway and suppressed endometrial cell viability and migration via targeting TGFBR1. Cell Cycle. 2020;19:1740–53.\nVanhie A, O D, Peterse D, Beckers A, Cuéllar A, Fassbender A, et al. Plasma miRNAs as biomarkers for endometriosis. Hum Reprod. 2019;34:1650–60.\nMadjid TH, Ardiansyah DF, Permadi W, Hernowo B. Expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in endometriosis menstrual blood. Diagnostics (Basel). 2020;10(6):364.\nBostanci Durmus A, Dincer Cengiz S, Yılmaz H, Candar T, Gursoy AY, Sinem CG. The levels of matrix metalloproteinase-9 and neutrophil gelatinase-associated lipocalin in different stages of endometriosis. J Obstet Gynaecol. 2019;39:991–5.\nWeigel MT, Krämer J, Schem C, Wenners A, Alkatout I, Jonat W, et al. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012;160:74–8.\nLiu C, Chen Y, Chen M, Mao X, Dong B, Sun P. A novel non-invasive molecular biomarker in ovarian endometriosis: estrogen-related receptor α. Arch Gynecol Obstet. 2020;302:405–14.\nProestling K, Wenzl R, Yotova I, Hauser C, Husslein H, Kuessel L. Investigating selected adhesion molecules as urinary biomarkers for diagnosing endometriosis. Reprod BioMed Online. 2020;40:555–8.\nKocbek V, Vouk K, Mueller MD, Rižner TL, Bersinger NA. Elevated glycodelin-A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecol Endocrinol. 2013;29:455–9.\nDrosdzol-Cop A, Skrzypulec-Plinta V. Selected cytokines and glycodelin A levels in serum and peritoneal fluid in girls with endometriosis. J Obstet Gynaecol Res. 2012;38:1245–53.\nLi Y, Chen Q. Circulating non-coding RNAs as non-invasive diagnostic markers of endometriosis: a comprehensive meta-analysis. Arch Gynecol Obstet. 2019;300:1099–112.\nJoseph S, Mahale SD. Endometriosis knowledgebase: a gene-based resource on endometriosis. Database (Oxford). 2019;2019:baz062.\nOrtiz-Muñoz B, Aznar-Oroval E, García García A, Covisa Peris A, Perez Ballestero P, Sanchez Yepes M, et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014;35:7249–58.\nJacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121:487–91.\nHuhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–9.\nZapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Abehsera D, et al. Utility serum marker HE4 for the differential diagnosis between endometriosis and adnexal malignancy. Int J Gynecol Cancer. 2016;26:52–5.\nBandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 2013;51:1815–24.\nBast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13:179–87.\nBast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–7.\nKrálíčková M, Losan P, Vetvicka V. Endometriosis and cancer. Womens Health (Lond). 2014;10:591–7.\nPittaway DE, Fayez JA. The use of CA-125 in the diagnosis and management of endometriosis. Fertil Steril. 1986;46:790–5.\nToki T, Kubota J, Lu X, Nakayama K. Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation. Acta Obstet Gynecol Scand. 2000;79:771–6.\nSütcü HK, Celik GIT, Akpak YK, Akar ME, Taşkın Ö, Ozdem S, et al. The value of CA-125, CA 19-9, Interleukin-6, Interleukin-8 and hsCRP in the diagnosis of endometriosis. Acta Medica Mediterranea. 2015;31:793–9.\nShinmura H, Yoneyama K, Harigane E, Tsunoda Y, Fukami T, Matsushima T, et al. Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma. Int J Gynecol Cancer. 2020;30:831–6.\nLi M, Tan J, Zhang Y, Ai C, Wang H, Zhang H, et al. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer. Abdom Radiol (NY). 2020;46:2367–75. https://doi.org/10.1007/s00261-020-02571-x.\nJing X, Li C, Sun J, Peng J, Dou Y, Xu X, et al. Systemic inflammatory response markers associated with infertility and endometrioma or uterine leiomyoma in endometriosis. Ther Clin Risk Manag. 2020;16:403–12.\nDing S, Lin Q, Zhu T, Li T, Zhu L, Wang J, et al. Is there a correlation between inflammatory markers and coagulation parameters in women with advanced ovarian endometriosis? BMC Womens Health. 2019;19:169.\nLiu S, Zhou J, Wen J. Expression and significance of CD133 and ABCG2 in endometriosis. Clin Exp Obstet Gynecol. 2015;42:771–5.\nTempest N, Maclean A, Hapangama DK. Endometrial stem cell markers: current concepts and unresolved questions. Int J Mol Sci. 2018;19(10):3240.\nKao AP, Wang KH, Chang CC, Lee JN, Long CY, Chen HS, et al. Comparative study of human eutopic and ectopic endometrial mesenchymal stem cells and the development of an in vivo endometriotic invasion model. Fertil Steril. 2011;95:1308–15.e1.\nChan RW, Ng EH, Yeung WS. Identification of cells with colony-forming activity, self-renewal capacity, and multipotency in ovarian endometriosis. Am J Pathol. 2011;178:2832–44.\nLiu Y, Liang S, Yang F, Sun Y, Niu L, Ren Y, et al. Biological characteristics of endometriotic mesenchymal stem cells isolated from ectopic lesions of patients with endometriosis. Stem Cell Res Ther. 2020;11:346.\nValentijn AJ, Palial K, Al-Lamee H, Tempest N, Drury J, Von Zglinicki T, et al. SSEA-1 isolates human endometrial basal glandular epithelial cells: phenotypic and functional characterization and implications in the pathogenesis of endometriosis. Hum Reprod. 2013;28:2695–708.\nSong Y, Xiao L, Fu J, Huang W, Wang Q, Zhang X, et al. Increased expression of the pluripotency markers sex-determining region Y-box 2 and Nanog homeobox in ovarian endometriosis. Reprod Biol Endocrinol. 2014;12:42.\nShariati F, Favaedi R, Ramazanali F, Ghoraeian P, Afsharian P, Aflatoonian B, et al. Increased expression of stemness genes REX-1, OCT-4, NANOG, and SOX-2 in women with ovarian endometriosis versus normal endometrium: a case-control study. Int J Reprod Biomed. 2019;16:ijrm.v16i12.3684.\nChang JH, Au HK, Lee WC, Chi CC, Ling TY, Wang LM, et al. Expression of the pluripotent transcription factor OCT4 promotes cell migration in endometriosis. Fertil Steril. 2013;99:1332–1339.e5.\nZhang Y, Eades G, Yao Y, Li Q, Zhou Q. Estrogen receptor α signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem. 2012;287(49):41514–22.\nYang L, Luo L, Ji W, Gong C, Wu D, Huang H, et al. Effect of low dose bisphenol A on the early differentiation of human embryonic stem cells into mammary epithelial cells. Toxicol Lett. 2013;218:187–93.\nAbramiuk M, Grywalska E, Korona-Glowniak I, Niedzwiedzka-Rystwej P, Polak G, Kotarski J, et al. CD200 and CD200R expression on peripheral blood lymphocytes and serum CD200 concentration as a new marker of endometriosis. J Clin Med. 2020;9. https://doi.org/10.3390/jmc9093035.\nNothnick WB. MicroRNAs and endometriosis: distinguishing drivers from passengers in disease pathogenesis. Semin Reprod Med. 2017;35:173–80.\nLi Y, Chen Q. Circulating non-coding RNA as non-invasive diagnostic markers of endometriosis: a comprehensive meta-analysis. Arch Gynecol Obstet. 2019;300:1099–112.\nPapari E, Noruzinia M, Kashani L, Foster WG. Identification of candidate microRNA markers of endometriosis with the use of next-generation sequencing and quantitative re3al-time polymerase chain reaction. Fertil Steril. 2020;113:1232–41.\nLiu C, Chen YJ, Chen M, Mao XD, Dong BH, Sun PM. A novel non-invasive molecular biomarker in ovarian endometriosis: estrogen-related receptor A. Arch Gynecol Obstet. 2020;302:405–14.\nAuthor information\nAuthors and Affiliations\nContributions\nAll the authors conform to the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, contributed to the intellectual content of the study, and approved the final version of the article.\nCorresponding author\nEthics declarations\nEthics approval\nThis article is a review and does not contain any research data collected and/or analyzed by the authors, so no formal ethical approval is required.\nConflict of interest\nThe authors declare no competing interests.\nAdditional information\nPublisher’s Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nKrálíčková, M., Vetvicka, V., Fiala, L. et al. The Search for Biomarkers in Endometriosis: a Long and Windy Road. Reprod. Sci. 29, 1667–1673 (2022). https://doi.org/10.1007/s43032-021-00668-2\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s43032-021-00668-2","source_license":"CC0","license_restricted":false}